Senti Biosciences (SNTI) Stock Overview
A clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
SNTI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Senti Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.04 |
| 52 Week High | US$5.10 |
| 52 Week Low | US$1.04 |
| Beta | 2.09 |
| 1 Month Change | -49.51% |
| 3 Month Change | -31.58% |
| 1 Year Change | -70.37% |
| 3 Year Change | -93.33% |
| 5 Year Change | n/a |
| Change since IPO | -98.96% |
Recent News & Updates
Recent updates
Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?
Dec 28
Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?
Sep 27Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platform
Sep 22Senti Biosciences GAAP EPS of -$0.86, revenue of $1.36M
Aug 16Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?
Jun 13Shareholder Returns
| SNTI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.6% | -2.6% | -1.4% |
| 1Y | -70.4% | 25.0% | 16.0% |
Return vs Industry: SNTI underperformed the US Biotechs industry which returned 25.4% over the past year.
Return vs Market: SNTI underperformed the US Market which returned 16.9% over the past year.
Price Volatility
| SNTI volatility | |
|---|---|
| SNTI Average Weekly Movement | 17.7% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SNTI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SNTI's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 34 | Tim Lu | www.sentibio.com |
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company’s product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma.
Senti Biosciences, Inc. Fundamentals Summary
| SNTI fundamental statistics | |
|---|---|
| Market cap | US$27.61m |
| Earnings (TTM) | -US$50.10m |
| Revenue (TTM) | n/a |
Is SNTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNTI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$37.60m |
| Gross Profit | -US$37.60m |
| Other Expenses | US$12.51m |
| Earnings | -US$50.10m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.91 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SNTI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/31 11:32 |
| End of Day Share Price | 2025/12/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Senti Biosciences, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Emily Bodnar | H.C. Wainwright & Co. |